Tag - SPRY

SVB Securities launched coverage of ARS Pharmaceuticals (NASDAQ:SPRY) with an “outperform” rating and $14 price target. The stock closed at $7.12 on Dec. 12. ARS is developing neffy, an intranasal epinephrine product in...